TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01617421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
Study: NCT00775918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
Study: NCT02765932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dummy Movements
Description: The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosensory Therapy
Description: The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
Study: NCT02571452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
Study: NCT03887377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Description: We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will serve as the placebo control on the contralateral breast
Study: NCT04396886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Bintrafusp alfa will be administered intravenously every 2 weeks
Study: NCT01299493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems-level intervention to promote colon cancer screening
Description: Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
Study: NCT00841867

Intervention type: PROCEDURE
Intervention: All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Description: All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.

Intervention type: PROCEDURE
Intervention: All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Description: All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
Study: NCT03660683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Saxagliptin 5 mg PO QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching Placebo Tablets
Study: NCT02543359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Models of PCIT
Description: Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Models of PCIT
Description: One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT) Treatment
Description: Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
Study: NCT00941603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271 15mg
Description: oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271 10 mg taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
Study: NCT03094689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Study: NCT02513654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
Study: NCT00593372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Training
Description: Increasing time to remember important information.
Study: NCT02488486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated postoperative sedation
Study: NCT00415142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration (capsules)
Study: NCT04538768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh augmentation
Description: P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct suture
Description: direct fascia suture
Study: NCT03829449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576 (Coversin)
Description: The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
Study: NCT02843698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
Study: NCT04590898

Intervention type: DEVICE
Intervention: Peri-device leakage closure after left atrial appendage occlusion
Description: Peri-device leakage closure after left atrial appendage occlusion
Study: NCT03046147

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery for morbid obesity

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery for morbid obesity
Study: NCT03061773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hospital treatment
Description: Conventional hospital treatment: The patients did not perform physical training
Study: NCT01315366

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D and Ci-CalD
Description: Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Euro D, Ci-CalD
Description: Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
Study: NCT02206724

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
Study: NCT01330615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
Study: NCT04737915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (In Vivo)
Description: Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (Virtual Reality)
Description: Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
Study: NCT04946422

Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Discharge diagnosis of patients with sports injury-related injuries
Study: NCT02451969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: investigational 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control 23-valent PPV
Description: The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
Study: NCT00389649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heart rate setting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heart rate setting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heart rate setting
Study: NCT01706770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A
Study: NCT02692352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal Management training, 8 sessions of 2 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Workshop
Description: Brain Health Workshop training, 8 sessions of 2 hours
Study: NCT03621020

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 PL Chip
Description: Flow chamber microchip system specific for measuring primary hemostatic ability

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 PL Chip
Description: Flow chamber microchip system specific for measuring primary hemostatic ability

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 PL Chip
Description: Flow chamber microchip system specific for measuring primary hemostatic ability

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 PL Chip
Description: Flow chamber microchip system specific for measuring primary hemostatic ability

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 PL Chip
Description: Flow chamber microchip system specific for measuring primary hemostatic ability

Intervention type: DIAGNOSTIC_TEST
Intervention: PFA-100 Col/Epi and Col/ADP
Description: System for measuring platelet dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: PFA-100 Col/Epi and Col/ADP
Description: System for measuring platelet dysfunction
Study: NCT02109627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT02374970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stability exercises
Description: Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized Physiotherapy
Description: Therapeutic exercises and thermotherapy during 12 daily sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized Physiotherapy
Description: Therapeutic exercises and thermotherapy during 12 daily sessions
Study: NCT01965743

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contraception Information Packet
Description: The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
Study: NCT03113864

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation for 9 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Daily Supplementation for 9 months
Study: NCT03621020

Intervention type: DIAGNOSTIC_TEST
Intervention: PFA-100 Col/Epi and Col/ADP
Description: System for measuring platelet dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: PFA-100 Col/Epi and Col/ADP
Description: System for measuring platelet dysfunction
Study: NCT04009057

Intervention type: OTHER
Intervention: B/F/TAF
Description: B/F/TAF administered in accordance with the approved product monograph
Study: NCT03886428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% portion size
Description: Entree portion size 100% of baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125% portion size
Description: Entree portion size 125% of baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150% portion size
Description: Entree portion size 150% of baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 175% portion size
Description: Entree portion size 175% of baseline
Study: NCT00868582

Intervention type: OTHER
Intervention: PET scanning in cancer
Description: Collection of institutional practice PET imaging data

Intervention type: OTHER
Intervention: PET scanning in cancer
Description: Collection of institutional practice PET imaging data
Study: NCT04407195

Intervention type: OTHER
Intervention: Exposure to the SARS-CoV-2
Description: This is an observational design. Participants are exposed to the Covid-19 pandemic.
Study: NCT03445247

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal low-intensity shockwave
Description: Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal low-intensity shockwave
Description: Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
Study: NCT01389206

Intervention type: DRUG
Intervention: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Description: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Study: NCT04084912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: intravenous injection of one ampoule saline
Study: NCT04238468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal stromal vascular fraction injection
Description: After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
Study: NCT02306603

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study: NCT05060952

Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin Lateral Flow Test
Description: Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate

Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin Lateral Flow Test
Description: Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate
Study: NCT04084028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Cooking Classes
Description: 6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
Study: NCT03068377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
Study: NCT02488486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Study: NCT03068377

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft gel capsules without test material
Study: NCT00941486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100 Ophthalmic Suspension
Description: FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A regimen of 2 drops 4 times a day while awake for 5 days.
Study: NCT01146119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001, 500 mcg
Description: Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001, 500 mcg
Description: Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001, 500 mcg
Description: Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvanted PBS
Description: Adjuvanted PBS was administered twice with an interval of 19-23 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PBS and TIV 15%
Description: PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PBS and TIV 50%
Description: PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.